Group 1 - The company is a leading domestic innovative pharmaceutical enterprise in the ADC and IO layout, with expectations for rapid market penetration of MRG003 upon approval [1] - The company has a robust product pipeline and is exploring business development opportunities abroad, indicating strong long-term growth potential [1] - The initial coverage rating is set to "Buy," with projected revenues of 853 million, 1.204 billion, and 1.665 billion yuan for 2025-2027, respectively [1] Group 2 - MRG003 has received priority review qualification from the CDE for the treatment of R/M NPC, with an NDA submission expected in March 2025, indicating a high likelihood of domestic approval soon [2] - In combination therapy, MRG003 has been officially included as a breakthrough therapy by the NMPA for patients with recurrent or metastatic nasopharyngeal carcinoma who have failed prior platinum and PD-1/L1 treatments [2]
乐普生物-B(2157.HK)：MRG003获批在即 联合PD-1大有可为-聚焦肿瘤免疫 ADC联合IO差异化竞